Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states

Thrombosis Research

Volumn 93, Issue 2, 1999, Pages 71-78

  López, Yolanda ^a   Paloma, Maria José ^b   Rifón, José ^a   Cuesta, Braulia ^a   Páramo, José A ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Universidad Pública de Navarra   (Spain)

Author keywords

Diabetes; Elderly; Hypercoagulability; Malignancy; Myocardial infarction; Pregnancy

Indexed keywords

BIOCHEMICAL MARKER; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRINOPEPTIDE A; PROTHROMBIN COMPLEX; THROMBIN ANTITHROMBIN COMPLEX;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD DISEASE; BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; DIABETES COMPLICATIONS; EVALUATION STUDIES; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; STATISTICS, NONPARAMETRIC; THROMBOPHILIA;

EID: 0345040153     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00165-0     Document Type: Article

References (36)

1. Bauer K.A., Rosenberg R.D. The pathophysiology of the prethrombotic state in humans. Insights gained from studies using markers of hemostatic system activation Blood. 70:1987;343-350.
2. Bick R.L., Pegram H. Syndromes of hypercoagulability and thrombosis. A review Sem Thromb Hemost. 20:1994;109-132.
3. Schafer A.I. The hypercoagulable states. Ann Intern Med. 102:1985;814-828.
4. Bauer K.A. New markers for in vivo coagulation. Curr Opin Hematol. 1:1994;341-346.
5. Mannucci P.M., Giangrande P.L.F. Detection of prethrombotic state due to procoagulant imbalance. Eur J Haematol. 48:1992;65-69.
6. Boisclair M.D., Ireland H., Lane D.A. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev. 4:1990;25-40.
7. Pelzer H., Schwarz A., Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 65:1991;153-159.
8. Pelzer H., Schwarz A., Heimburger N. Determination of human thrombin-antithrombin complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 59:1988;101-106.
9. Amiral J., Walenga J.M., Fareed J. Development of a competitive enzyme immunoassay for fibrinopeptide A. Sem Thromb Hemost. 10:1984;228-242.
10. 2-antiplasmin-plasmin complex in human plasma with an enzyme-linked immunosorbent assay. Fibrinolysis. 7:1993;69-74.
11. Koppert P.W., Hoegee-de Nobel E., Nieuwenhuizen W. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products. Thromb Haemost. 59:1988;310-315.
12. Mari D., Mannucci P.M., Coppola R., Bottasso B., Bauer K.A., Rosenberg R.D. Hypercoagulability in centenarians. The paradox of successful aging Blood. 85:1995;3144-3149.
13. Hamilton P.J., Allardyce M., Ogston D., Dawson A.A., Douglas A.S. The effect of age upon the coagulation system. J Clin Pathol. 27:1974;980-982.
14. Bauer K.A., Weiss L.M., Sparrow D., Vokonas P.S., Rosenberg R.D. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative aging study. J Clin Invest. 80:1987;1527-1534.
15. Cadroy Y., Pierrejean D., Fontan B., Sié P., Boneu B. Influence of aging on the activity of the hemostatic system:prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. Nouv Rev Fr Hematol. 34:1992;43-46.
16. Stirling Y., Woolf L., North W.R.S., Seghatchian M.J., Meade T.W. Haemostasis in normal pregnancy. Thromb Haemost. 52:1984;176-182.
17. Cadroy Y., Grandjean H., Pichon J., Desprats R., Berrebi A., Fournie A., Boneu B. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol. 100:1993;416-420.
18. Reinthaller A., Mursch-Edlmayr G., Tatra G. Thrombin-antithrombin III complex levels in normal pregnancy with hypertensive disorders and after delivery. Br J Obstet Gynaecols. 97:1990;506-510.
19. Ballegeer V., Mombaerts P., Declerck P.J., Spitz B., Van Assche F.A., Collen D. Fibrinolytic response to venous occlusion and fibrin fragment D-dimer levels in normal and complicated pregnancy. Thromb Haemost. 58:1987;1030-1032.
20. Kruithof E.K.O., Tran-Thang C., Gudinchet A., Hauert J., Nicoloso G., Genton C., Welti H., Bachman F. Fibrinolysis during pregnancy. A study of plasminogen activator inhibitors Blood. 69:1987;460-466.
21. Fletcher A.P., Alkjaersig N., Burstein R. The influence of pregnancy upon blood coagulation and plasma fibrinolytic enzyme function. Am J Obstet Gynecol. 134:1979;743-751.
22. Rocha E., Páramo J.A. Predisposition to thrombotic complications in diabetes mellitus. Glas-Greenwalt P. Fibrinolysis in Disease. Molecular and Hemovascular Aspects of Fibrinolysis:1995;165-171 CRC Press, Boca Raton, Florida.
23. Jones R.L. Fibrinopeptide A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. Diabetes. 34:1985;836-843.
24. Davi G., Gennaro F., Spatola A., Catalano I., Averna M., Montalto G., Amato S., Notarbartolo A. Thrombin-antithrombin III complexes in type II diabetes mellitus. J Diabetes Complications. 6:1992;7-11.
25. Ceriello A., Giacomello R., Stel G., Motz E., Taboga C., Tonutti L., Pirisi M., Falleti E., Bartoli E. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes. 44:1995;924-928.
26. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res. 70:1993;1-38.
27. Szczeklik A., Dropinski J., Radwan J., Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb. 12:1992;548-553.
28. Merlini P.A., Bauer K.A., Oltrona L., Ardissino D., Cattaneo M., Belli C., Mannucci P.M., Rosenberg R.D. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 90:1994;61-68.
29. Rocha E., Páramo J.A. The relationship between impaired fibrinolysis and coronary heart disease. A role for PAI-1 Fibrinolysis. 8:1994;294-303.
30. Ridker P.M., Hennekens C.H., Cerskus A., Stampfer M.J. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 90:1994;2236-2240.
31. Rickles F.R., Edwards R.L. Activation of blood coagulation in cancer. Trousseau's syndrome revisited Blood. 62:1983;14-31.
32. Rocha E., Páramo J.A., Fernández F.J., Cuesta B., Hernández M., Paloma M.J., Rifón J. Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res. 54:1989;699-707.
33. Myers T.J., Rickles F.R., Barb C., Cronlund M. Activation of blood coagulation in acute leukemia-fibrinopeptide A (FPA) generation as an indicator of disease activity. Blood. 57:1981;518-525.
34. Rickles F.R., Edwards R.L., Barb C., Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer. 51:1983;301-307.
35. Imaoka S., Sasaki Y.O., Iwanaga T., Terasawa T. The significance of the fibrin/fibrinogen degradation product in serum of carcinoma patients with hematogenous metastasis. Cancer. 58:1986;1488-1492.
36. Páramo J.A., Campbell W., Cuesta B., Gómez C., Aranda A., Rocha E. Fibrinolytic response in malignancy. Fibrinolysis. 1:1987;195-199.